Tags |
|
|
Links |
|
|
Wiki Articles - Borrowing To Invest In Stocks And Shares - A Risky Tactic?
In the heyday of the stockmarket boom of the 1990s, there were regular stories of investors making massive returns in
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
a matter days. This was in the period of the so called “technology bubble” but as with all bubbles, it finally burs
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
t with serious consequences for many investors. Can borrowing to invest ever really work?
While the strategy of usi
While the strategy of usi
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
g borrowed funds to invest is always going to be a risky strategy, there are ways in which you can reduce the risk.
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
If you decide to take this path, you should consider the following factors :-
Level Of Risk
Before even looking int
Level Of Risk
Before even looking int
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
o borrowing to invest, you need to consider what level of risk you are willing to take, and what investment return yo
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
are looking for. With a higher return comes a higher risk, so you need to find a suitable balance for your own pers
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
onal situation.
Term Of Investment
While long term investments are often more lucrative, and deemed to be less risk
Term Of Investment
While long term investments are often more lucrative, and deemed to be less risk
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
y by many, there are risks with any investment. Stocks and shares are notoriously volatile with many factors contribu
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
ing to any future change in share price values - some of the factors are out of control of even the directors of a pa
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
rticular company, e.g. world recession, terrorist threat, etc.
Asset Backing
Many investors who look to borrow to i
Asset Backing
Many investors who look to borrow to i
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
nvest will already have assets behind them, which they can fall back on in the event that the “funded” investments do
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
not work to plan. This is perhaps the best form of financed investment, but whether you choose to go ahead with or w
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
ithout backing - you will ultimately pay the price if it all goes wrong.
Experience
Do you have the expertise, or k
Experience
Do you have the expertise, or k
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
now of suitable advisers, which will increase the chances of you being successful? Many people who struggled in the
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
ftermath of the 1990s did so because they were “following the crowd” without the necessary experience. This show of “
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
irrational exuberance” is often a sign that a stockmarket is becoming over heated.
While it is true that many invest
While it is true that many invest
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
ors have made big money from “funded” investments, it is not suitable for everyone. It is difficult enough to make su
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
table investment returns with “free money”, never mind with the extra pressure from using borrowed funds. Unless yo
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
u have the experience and nerve to take in the good and bad days , you should think twice about entertaining the idea
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.wiki-articles.org.ua/article/116875/wiki-articles-Borrowing-To-Invest-In-Stocks-And-Shares--A-Risky-Tactic.html">Borrowing To Invest In Stocks And Shares - A Risky Tactic?</a>
BB link (for phorums):
[url=http://www.wiki-articles.org.ua/article/116875/wiki-articles-Borrowing-To-Invest-In-Stocks-And-Shares--A-Risky-Tactic.html]Borrowing To Invest In Stocks And Shares - A Risky Tactic?[/url]
Related Articles:
Don’t Forget the Basics of Cover Letter Writing
What Are The Hottest PPC Tools Today
Bookmark it:
|